Source comparison
DAC vs Non-DAC Formulations Change Weekly Frequency
CJC-1295 exists in two distinct formulations. CJC-1295 DAC (Drug Affinity Complex) and CJC-1295 without DAC, also called modified GRF(1-29). And the structural difference between them fundamentally alters optimal dosing frequency for recovery applications. Thi
This comparison does not assign a generated winner or score.
- CJC-1295 exists in two distinct formulations. CJC-1295 DAC (Drug Affinity Complex) and CJC-1295 without DAC, also called modified GRF(1-29). And the structural difference between them fundamentally alters optimal dosing frequency for recovery applications. This is not a minor detail. DAC modification extends the peptide's half-life from under 30 minutes to approximately 6–8 days, shifting it from a pulsatile agonist to a sustained-release compound.
- CJC-1295 without DAC (modified GRF 1-29) mimics natural GHRH release kinetics. It binds GHRH receptors, triggers a GH pulse, and clears from circulation within 30 minutes. This short half-life allows multiple weekly doses without receptor desensitization. The standard protocol is 200–300mcg administered 2–3 times per week, timed 30–60 minutes before sleep to align with circadian GH peaks. Research using this formulation shows preserved pulsatility across 8–12 week cycles with no significant attenuation of response.
- CJC-1295 with DAC, by contrast, remains bioavailable for days after a single injection. The extended half-life produces sustained GH elevation rather than discrete pulses. A pharmacokinetic profile that more closely resembles exogenous GH administration than endogenous GHRH signaling. Because the peptide stays active, dosing frequency drops to once or twice weekly at 500–1000mcg per dose. The trade-off: continuous receptor occupancy can blunt natural pulsatile release over time, a phenomenon observed in clinical trials where DAC formulations showed diminishing GH response after 6–8 weeks of uninterrupted use.
- For recovery-focused protocols, modified GRF(1-29) without DAC is the more physiologically aligned choice. It preserves the body's natural GH rhythm while amplifying peak amplitude. Allowing tissue repair processes to scale with training stress without disrupting baseline endocrine function. DAC formulations have applications in contexts requiring steady-state GH elevation, but for athletes cycling training intensity, the pulsatile model matches recovery demand more precisely. The decision between formulations is not about potency. It's about matching peptide kinetics to recovery physiology.